The message below is a paid advertisement. Content is provided by the sponsor.

With nearly a decade of commercial use, Confirm mdx remains the only tissue-based assay detecting DNA methylation to help risk stratify patients following a negative prostate biopsy. As MRI, biomarkers, and fusion biopsy continue to reshape the diagnostic landscape, Confirm mdx remains the only tissue-based assay detecting DNA methylation to help risk stratify patients following a negative prostate biopsy.

Now available on-demand, join Dr. Jose De La Cerda, a urologist with extensive experience integrating Confirm mdx alongside modern imaging and biopsy techniques, as he discusses his clinical approach to patient management based on Confirm mdx positive and negative results.

In this educational webinar, Dr. De La Cerda also reviews:

  • Real-world case studies with concordant repeat biopsy outcomes
  • How he incorporates Confirm mdx alongside MRI and fusion biopsy
  • Practical insights into post-negative biopsy management
  • Audience Q&A discussion
Watch Webinar on Demand

Jose De La Cerda, III, MD, MPH
Urologist
Urology San Antonio
San Antonio, Texas